Morphovascular changes after anti-VEGF intravitreal injection for a choroidal neovascularization secondary to COVID-19 infection in a pediatric patient.
Adolescent
Humans
Child
Vascular Endothelial Growth Factor A
Angiogenesis Inhibitors
/ therapeutic use
Intravitreal Injections
Quality of Life
Photosensitizing Agents
/ therapeutic use
Photochemotherapy
/ methods
COVID-19
/ complications
Ranibizumab
/ therapeutic use
Choroidal Neovascularization
/ drug therapy
Macula Lutea
Tomography, Optical Coherence
Fluorescein Angiography
Retrospective Studies
Anti-VEGF
Choroidal neovascularization
Covid-19
Optical coherence tomography angiography
Journal
Photodiagnosis and photodynamic therapy
ISSN: 1873-1597
Titre abrégé: Photodiagnosis Photodyn Ther
Pays: Netherlands
ID NLM: 101226123
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
21
02
2023
revised:
17
04
2023
accepted:
18
04
2023
medline:
3
7
2023
pubmed:
22
4
2023
entrez:
21
04
2023
Statut:
ppublish
Résumé
Choroidal neovascularization (CNV) is a common pathologic lesion that occurs in various chorioretinopathy. Although the incidence of CNV is quite rare in children and adolescents, these lesions have a severe impact on visual acuity and quality of life over patients' lifetime. The management of CNV in pediatric patients is challenging, clear guidelines are limited due to a lack of randomized clinical trials. However, the more promising option is the use of vascular endothelial growth factor (VEGF) inhibitors. We reported a case of recurrent idiopathic choroidal neovascularization in a healthy pediatric patient after COVID 19 infection. Optical coherence tomography angiofraphy (OCTA) showed, in a non invasive way, a choroidal neovascularization at the posterior pole including macula and superior temporal arcade in the right eye, while the left eye was unaffected. In order to inactivate the neovascularization, intravitreal injections of anti-VEGF (Lucentis-Ranibizumab 0.3 mL) were performed in the right eye. Six months after the injections BCVA of the right eye was improved from 0.7 logMAR to 0.2 logMAR. OCT-A examination did not detect any signs of attivation of the preexistent neovascularization. It is reasonable to assert that Anti-VEGF could be the main treatment in case of choroidal neovascularization in young patients after COVID 19 infection due to the high chorioretinal level of VEGF-A described in these diseases.
Identifiants
pubmed: 37084932
pii: S1572-1000(23)00304-6
doi: 10.1016/j.pdpdt.2023.103577
pii:
doi:
Substances chimiques
Vascular Endothelial Growth Factor A
0
Angiogenesis Inhibitors
0
Photosensitizing Agents
0
Ranibizumab
ZL1R02VT79
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
103577Informations de copyright
Copyright © 2023 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.